Komori
Kidswell Bio (4584) · InitiativeAchieved

Covering the Deficit Through Reductions in Stated Capital and Capital Reserves and Greater Flexibility in Capital Policy

First written in FY2017. 2 of 5 entries say "Achieved", first in FY2018-Q1. Latest entry: FY2026-H1.

5entries
9years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseCited as achievedFY20182017: 220172018: 120182019: 020192020: 020202021: 020212022: 020222023: 020232024: 020242025: 22025
Same theme, other companies
Capital Policy and Dividend Preparation through Capital Reduction and Deficit EliminationA theme 287 companies write about · 1 as a headwind · 286 as a tailwind

127 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 200 companies compared. The sentences above are computed from all 200.Comparing 200 of the theme's 289 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026-H1AchievedAnnual report

    「Pursuant to a resolution at the Annual General Meeting of Shareholders held on 27 June 2025, the company reduced stated capital by ¥2,486,206 thousand and capital reserves by ¥11,841,807 thousand, increased other capital surplus by ¥14,328,013 thousand, and then transferred ¥11,902,990 thousand to retained earnings brought forward to cover the deficit.」

    Regarding the coverage of the deficit through reductions in stated capital and capital reserves and the transfer from other capital surplus to retained earnings brought forward, the reduction in capital took effect on 1 August 2025 and was completed.
  2. FY2025AdvancedAnnual report

    「At a meeting of the Board of Directors held on 14 May 2025, the company resolved to submit proposals on the reduction of stated capital and capital reserves and the disposition of surplus to the 25th Annual General Meeting of Shareholders to be held on 27 June 2025.」

    The company reached the stage of once again advancing a capital policy to reduce stated capital and capital reserves, transfer other capital surplus to retained earnings brought forward, and cover the deficit. The planned effective date is 1 August 2025.
  3. FY2018Cited as achievedAnnual report

    「At the 17th Annual General Meeting of Shareholders held on 28 June 2017, the company received approval for the reduction of stated capital and capital reserves and the disposition of surplus, which took effect on 1 August 2017.」

    The company has reaffirmed, based on the statements of changes in shareholders' equity and other documents, that the reduction of stated capital and capital reserves and the deficit disposition have taken effect as a completed capital policy.
  4. FY2018-Q1AchievedAnnual report

    「At the 17th Annual General Meeting of Shareholders held on 28 June 2017, the company received approval for the reduction of stated capital and capital reserves and the disposition of surplus, which took effect on 1 August 2017.」

    Regarding the coverage of the deficit through reductions in stated capital and capital reserves and the disposition of surplus, the measures took effect on 1 August 2017 following approval at the General Meeting of Shareholders. The company reduced stated capital by ¥4,094,243,331 and capital reserves by ¥724,525,178 to cover a ¥4,818,768,509 deficit in retained earnings brought forward.
  5. FY2017First statedAnnual report

    「For the purpose of covering this deficit, strengthening the company's financial position, and securing flexibility and agility in its future capital policy, the company will reduce the amounts of stated capital and capital reserves under Articles 447(1) and 448(1) of the Companies Act and dispose of surplus under Article 452.」

    With 1 August 2017 as the effective date, the company first disclosed a capital policy involving reductions in stated capital and capital reserves to cover a ¥4,818,768,509 deficit in retained earnings brought forward.
Moved together

"A Hybrid Business Model Building Stability through Biosimilars and Pursuing Growth through Novel Biologics" moved the same way as this thread, in the same document, in 2 of its 5 moves.

222222★123456
  1. ★This thread
  2. 1A Hybrid Business Model Building Stability through Biosimilars and Pursuing Growth through Novel Biologics2×
  3. 2Early Profitability and Strengthening the Financial Condition2×
  4. 3Securing a Competitive Product Advantage through Active Pharmaceutical Ingredient Quality, Manufacturing Costs, and Usability2×
  5. 4Four-party joint research on a treatment for cerebral palsy using dental pulp stem cells2×
  6. 5Initiation of company-led clinical trials from 2025 onward2×
  7. 6Enhancing Development Capabilities and Speed Through Partnerships with Contract Research Organizations and Pharmaceutical Companies2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Kidswell Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Covering the Deficit Through Reductions in Stated Capital and Capital Reserves and Greater Flexibility in Capital Policy | Kidswell Bio Corporation (4584) | Komori